Librando, Elyn .
HRN: 20-62-45 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/12/2024
CO-AMOXICLAV 625MG (TAB)
11/12/2024
11/19/2024
ORAL
625mg
3x A Day
S/p NSVD
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes